🔍

AMANTA - Amanta Healthcar

📊 NSE: AMANTA 🏢 Pharmaceuticals 📅 Last Updated: 11/13/2025 15:25

📢 Recent Corporate Announcements

Amanta Healthcare Clarifies Promoter Share Acquisition; Total Holding Rises to 16.29%

🟢 POSITIVE ⭐ 4/10

REGULATORY 📅 22 Apr 2026, 05:02 PM

Amanta Healthcare has issued a clarification regarding the acquisition of shares by its promoter, Shri Bhavesh Patel. The company clarified that 15,500 additional shares were credited to the promoter's account on April 17, 2026, following a purchase made on March 30, 2026. This completes the credit of 28,800 shares previously disclosed. As a result, the promoter's total holding has increased from 16.25% to 16.29%, representing a marginal increase in skin-in-the-game.

Promoter Bhavesh Patel acquired a total of 28,800 equity shares via market purchase on March 30, 2026
Clarification confirms the credit of the remaining 15,500 shares into the demat account on April 17, 2026
Total promoter holding increased from 63,11,044 shares (16.25%) to 63,26,544 shares (16.29%)
The filing was made to rectify earlier disclosures under SEBI (Prohibition of Insider Trading) Regulations

💡 Investors should view this as a minor positive signal of promoter confidence. While the 0.04% stake increase is small, consistent promoter buying often indicates perceived undervaluation by management.

Amanta Healthcare Clarifies Promoter Share Acquisition Downward to 13,300 Shares

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 18 Apr 2026, 04:11 PM

Amanta Healthcare has issued a clarification regarding a previous disclosure of share acquisition by its promoter, Shri Bhavesh Patel. While the initial report stated an acquisition of 28,800 shares, the company now confirms that only 13,300 shares were successfully credited to the demat account. The discrepancy arose due to technical rejections affecting 15,500 shares during the transfer process. Consequently, the promoter's post-acquisition stake stands at 16.25%, which is a marginal increase from the previous 16.22%.

Promoter Shri Bhavesh Patel's actual share acquisition revised from 28,800 to 13,300 shares
Technical reasons led to the rejection of 15,500 shares during the transfer process
Promoter's total holding increased from 16.22% (62,97,744 shares) to 16.25% (63,11,044 shares)
The transactions were originally executed on March 27 and March 30, 2026

💡 Investors should update their records to reflect the corrected promoter holding of 16.25%. This is a minor administrative correction and does not change the overall positive signal of a promoter increasing their stake.

Amanta Healthcare Reports Resignation of AVP HR & Admin Vimal Shrimali

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 16 Apr 2026, 02:36 PM

Amanta Healthcare Limited has announced the resignation of Shri Vimal Shrimali, who held the position of Assistant Vice President (AVP) – HR & Admin. As a designated Senior Management Personnel (SMP), his departure is being disclosed under Regulation 30 of the SEBI Listing Regulations. The resignation is effective from the close of business hours on April 16, 2026. The company has cited personal reasons for this change in the senior management team.

Shri Vimal Shrimali resigned as AVP – HR & Admin effective April 16, 2026
The resignation is categorized as a change in Senior Management Personnel under SEBI (LODR) Regulations
The official reason for the departure is stated as personal reasons
The company has acknowledged the resignation and completed the necessary regulatory filings

💡 This is a routine administrative change in the HR department and is unlikely to impact the company's financial performance. No immediate action is required from investors.

Amanta Healthcare Promoters Confirm Zero Pledged Shares for FY 2025-26

🟢 POSITIVE ⭐ 4/10

REGULATORY 📅 10 Apr 2026, 12:37 PM

Amanta Healthcare Limited has filed its annual disclosure under Regulation 31(4) of the SEBI (SAST) Regulations for the financial year ending March 31, 2026. The promoter and promoter group have officially declared that no shares or securities of the company were encumbered, directly or indirectly, during the entire fiscal year. This routine regulatory filing confirms that the promoters have not pledged their holdings to raise debt. Such disclosures are critical for maintaining transparency regarding the financial health and stability of the company's leadership.

Promoters declared zero encumbrance on company shares for the financial year 2025-26.
Compliance filing submitted under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Declaration issued by Bhavesh G. Patel, Promoter and Chairman & Managing Director.
The disclosure covers the full reporting period ending March 31, 2026.

💡 Investors should take this as a positive sign of promoter stability and financial health, as unencumbered shares reduce the risk of forced liquidations. No immediate portfolio action is required based on this routine compliance filing.

Amanta Healthcare Submits Share Capital Audit Report for Quarter Ended March 31, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 09 Apr 2026, 05:27 PM

Amanta Healthcare Limited has filed its Reconciliation of Share Capital Audit Report for the quarter ended March 31, 2026, as required under SEBI Regulations. The audit, conducted by M/s Kashyap R. Mehta & Partners, ensures that the company's total issued capital matches the shares held in NSDL, CDSL, and physical form. This is a standard regulatory filing aimed at maintaining transparency in the company's shareholding structure. No discrepancies or material changes were reported in this announcement.

Submission of Reconciliation of Share Capital Audit Report for Q4 FY26
Compliance with Regulation 76 of SEBI (Depositories and Participants) Regulations, 2018
Audit certified by M/s Kashyap R. Mehta & Partners, Company Secretaries
Verification of total issued capital against electronic and physical holdings

💡 No action is required as this is a routine compliance filing. Investors should focus on upcoming financial results for a better understanding of the company's growth trajectory.

Amanta Healthcare Concludes Site Visit and Group Meeting with Institutional Investors

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 09 Apr 2026, 10:14 AM

Amanta Healthcare Limited successfully conducted a site visit and group meeting with analysts and institutional investors on April 7, 2026. The company confirmed that the interaction focused on publicly available information, ensuring no Unpublished Price Sensitive Information (UPSI) was shared. This meeting follows a prior regulatory intimation made on April 2, 2026, regarding the scheduled visit. Such interactions are standard for institutional due diligence and understanding of the company's manufacturing operations.

Site visit and group meeting with institutional investors completed on April 7, 2026.
Compliance maintained under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The company explicitly stated that no Unpublished Price Sensitive Information (UPSI) was discussed.
Follow-up to the initial intimation provided to stock exchanges on April 2, 2026.

💡 Investors should look for any subsequent research reports from participating institutions for qualitative insights into the company's operations. No immediate portfolio changes are recommended based on this routine disclosure.

Amanta Healthcare Submits Q4 FY26 SEBI Compliance Certificate for Dematerialization

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 08 Apr 2026, 10:15 AM

Amanta Healthcare Limited has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations for the period ending March 31, 2026. The Registrar and Share Transfer Agent, MUFG Intime India Private Limited, confirmed that all dematerialization requests were handled according to regulatory standards. The filing confirms that physical share certificates were mutilated and cancelled after verification, and the depositories were updated as registered owners. This routine disclosure ensures the integrity of the company's shareholding records and adherence to SEBI timelines.

Quarterly compliance certificate submitted for the period ending March 31, 2026
Registrar MUFG Intime India confirms processing of dematerialization requests within prescribed timelines
Physical security certificates were mutilated and cancelled after due verification by the depository participant
Confirmation that securities comprised in the certificates are listed on the BSE and NSE

💡 This is a routine administrative update confirming regulatory compliance; no specific action is required from investors.

Amanta Healthcare to Host Institutional Investor Site Visit on April 7, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 02 Apr 2026, 05:49 PM

Amanta Healthcare Limited has announced a group meeting and site visit for analysts and institutional investors scheduled for April 7, 2026. The meeting will take place in person at the company's manufacturing facility in Kheda, Gujarat. This interaction is part of the company's routine investor relations activities under SEBI (LODR) Regulations. The company has confirmed that no unpublished price sensitive information (UPSI) will be shared during the visit.

Event: In-person group meeting and site visit for institutional investors
Date: Scheduled for Tuesday, April 7, 2026
Location: Factory site at 876, N.H. No. 8, Hariyala, Kheda, Gujarat
Compliance: Disclosed under Regulation 30 of SEBI (LODR) Regulations, 2015

💡 No immediate action is required as this is a routine disclosure. Investors should look for any post-visit presentations or transcripts that may be filed with the exchanges for insights into operational capacity.

Amanta Healthcare Promoters Declare Zero Encumbrance for FY 2025-26

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 02 Apr 2026, 02:29 PM

Amanta Healthcare Limited has submitted its annual disclosure under Regulation 31(4) of the SEBI (SAST) Regulations for the financial year ended March 31, 2026. The promoter and promoter group have declared that no shares of the company were encumbered, directly or indirectly, during the entire fiscal year. This filing is a standard annual compliance requirement confirming that promoter holdings remain free of pledges or liens. The declaration was signed by the Chairman and Managing Director, Bhavesh G. Patel.

Annual disclosure submitted for the financial year ending March 31, 2026
Promoter group declared zero direct or indirect encumbrances on company securities
Compliance maintained under Regulation 31(4) of SEBI (SAST) Regulations, 2011
Declaration covers the full 12-month period of FY 2025-26

💡 No action is required as this is a routine regulatory filing confirming the absence of promoter share pledges. It reflects a stable ownership structure with no new financial encumbrances on promoter stakes.

Amanta Healthcare Promoter Bhavesh Patel Acquires 28,800 Shares via Open Market

🟢 POSITIVE ⭐ 6/10

OTHER 📅 01 Apr 2026, 02:44 PM

Shri Bhavesh Patel, the Promoter, Chairman, and Managing Director of Amanta Healthcare, has purchased 28,800 equity shares of the company. These transactions were conducted through the open market on March 27 and March 30, 2026. The disclosure was made in compliance with SEBI (Prohibition of Insider Trading) Regulations. Such insider buying by the top-most executive is generally perceived as a strong signal of confidence in the company's future performance and valuation.

Promoter and CMD Shri Bhavesh Patel acquired 28,800 equity shares from the open market.
The acquisition took place across two trading sessions on March 27 and March 30, 2026.
Disclosure filed under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.
The purchase reflects management's direct financial commitment to the company's growth trajectory.

💡 Investors should take this as a positive cue regarding the company's internal outlook. It is advisable to monitor if the promoter continues to increase their stake in subsequent quarters.

Amanta Healthcare Announces Trading Window Closure from April 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 28 Mar 2026, 03:05 PM

Amanta Healthcare Limited has informed the stock exchanges that its trading window will be closed starting April 1, 2026. This closure is a mandatory compliance step under SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the company's annual financial results. The window will remain closed for all designated persons and their immediate relatives until 48 hours after the audited financial results for the fiscal year ending March 31, 2026, are declared. This is a standard procedure to ensure no insider trading occurs before price-sensitive information is public.

Trading window closure effective from April 01, 2026
Closure is related to the Audited Financial Results for the year ended March 31, 2026
Window to reopen 48 hours after the financial results are submitted to the exchanges
Applies to all Insiders, Connected Persons, and Designated Persons of the company

💡 No action is required as this is a routine regulatory filing. Investors should look forward to the upcoming board meeting announcement for the actual FY2026 financial performance.

Amanta Healthcare Promoter Bhavesh Patel Acquires 48,151 Shares via Open Market

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 27 Feb 2026, 05:00 PM

Shri Bhavesh Patel, a promoter of Amanta Healthcare Limited, has increased his stake by purchasing 48,151 equity shares from the open market. The acquisition took place over two trading sessions on February 26 and February 27, 2026. This transaction was disclosed under the SEBI (Prohibition of Insider Trading) Regulations, 2015. Such insider buying typically signals strong promoter confidence in the company's future prospects and intrinsic value.

Promoter Shri Bhavesh Patel purchased a total of 48,151 equity shares.
The acquisition was conducted through open market transactions on February 26 and 27, 2026.
The disclosure was filed in compliance with Regulation 7(2) of SEBI Insider Trading rules.
The move indicates increased 'skin in the game' by the promoter group.

💡 Investors should view this promoter buying as a positive sign of internal confidence, though it should be weighed against the company's overall financial performance.

CRISIL Upgrades Amanta Healthcare’s Long-Term Rating to 'BBB/Stable' on Improved Financial Profile

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 16 Feb 2026, 04:32 PM

CRISIL has upgraded Amanta Healthcare's long-term rating to 'BBB/Stable' and short-term rating to 'A3+', reflecting a significantly strengthened financial position. The upgrade follows a successful IPO that raised Rs 126 crore, boosting net worth to Rs 211 crore as of September 2025 and reducing gearing from 2.02 to 0.84. The company maintains healthy operating margins of 21-22% and is expanding capacity for its Steriport and SVP brands, expected to go live in April 2026. This improved credit profile suggests lower borrowing costs and better financial stability for future growth.

Long-term credit rating upgraded to 'CRISIL BBB/Stable' from 'CRISIL BBB-/Stable' for Rs 245 crore bank facilities.
Net worth increased to Rs 211 crore from Rs 96 crore following a Rs 126 crore IPO infusion.
Debt-to-equity (gearing) ratio improved significantly to 0.84x from 2.02x as of September 2025.
Operating margins remain healthy at approximately 22% for the first half of fiscal 2026.
Capacity expansion for Steriport and SVP brands is scheduled for completion by April 2026 to drive future revenue.

💡 Investors should view this upgrade as a sign of reduced financial risk and improved balance sheet strength following the IPO. Monitor the timely commencement of the new capacity in April 2026 as it is the primary catalyst for medium-term growth.

Amanta Healthcare Q3 PAT Rises 8.1%; Targets ₹150 Cr Incremental Revenue from Expansion

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 16 Feb 2026, 02:37 PM

Amanta Healthcare reported a steady Q3 FY26 with revenue growing 9.8% YoY to ₹75 crores and PAT increasing 8.1% to ₹5 crores. The company is nearing a major growth phase, doubling its SteriPort capacity to 12 crore bottles per annum with commercialization expected in April 2026. Management anticipates an incremental revenue potential of ₹150 crores from the combined LVP and SVP expansions. Additionally, a 10.8 MW captive solar plant is expected to save ₹9 crores annually starting Q1 FY27, which will significantly enhance operating leverage.

Q3 FY26 revenue grew 9.8% YoY to ₹75 crores, while 9M PAT surged 51% YoY to ₹9 crores.
SteriPort capacity doubling to 12 crore bottles/year with commercialization slated for April 2026.
Total incremental revenue potential of ₹150 crores from SteriPort and SVP expansions.
10.8 MW captive solar plant to be commissioned by Q1 FY27, targeting ₹9 crores in annual cost savings.
EBITDA margins remained healthy at 21.3% for the 9-month period despite one-time IPO expenses.

💡 Investors should monitor the successful ramp-up of the new SteriPort capacity in April 2026 as it is the primary driver for the projected ₹150 crore revenue growth. The stock remains attractive for long-term investors given the improving return ratios and structural cost advantages from the upcoming solar project.

Amanta Healthcare Publishes Q3 FY26 Financial Results in Newspapers

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 12 Feb 2026, 02:13 PM

Amanta Healthcare Limited has formally published its financial results for the quarter ended December 31, 2025, in compliance with SEBI regulations. The results were previously approved by the Board of Directors in their meeting held on February 10, 2026. The advertisements appeared in the February 12, 2026, editions of Business Standard (English) and Jai Hind (Gujarati). This is a standard regulatory procedure and does not contain new financial data beyond what was already disclosed to the exchanges.

Financial results for the quarter ended December 31, 2025, were published on February 12, 2026.
The Board of Directors approved the quarterly results on February 10, 2026.
Publications were made in Business Standard (English) and Jai Hind (Gujarati) newspapers.
Filing is in accordance with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

💡 No action is required as this is a routine regulatory filing. Investors should refer to the actual financial statements released on February 10 to evaluate the company's quarterly performance.

View All AMANTA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total revenue grew 8.5% YoY to INR 281 Cr in FY24 from INR 259 Cr in FY23. Growth is primarily driven by the fluid therapy segment (LVP and SVP) and the high-margin Steriport segment. For H1 FY25, the company reported sales of INR 140 Cr, with a projected annual growth of 8-10% for the full fiscal year 2025.

Geographic Revenue Split

The company maintains a presence in both domestic and international markets, including Cambodia and Zimbabwe. While specific percentage splits are not disclosed, exports are identified as a primary driver for the projected 8-10% revenue growth in FY25 and are expected to increase further following the Steriport capacity expansion.

Profitability Margins

Operating margins have remained steady between 20-22% over the last five fiscals. The margin was 20.7% in FY24 and improved to approximately 22% during the first five months of FY25. PAT margin improved from -0.8% (INR -2 Cr loss) in FY23 to 1.3% (INR 4 Cr profit) in FY24.

EBITDA Margin

Operating EBITDA margin stood at 20.7% in FY24. The company maintains a core profitability range of 20-22%, which is supported by a shift toward high-value specialty products like Steriport and cost optimization measures, despite volatility in raw material costs.

Capital Expenditure

Planned capital expenditure of INR 90 Cr is scheduled for fiscals 2025 and 2026 to expand Steriport capacity. This is funded through INR 40 Cr in debt, INR 20 Cr via private placement of equity, and the remaining INR 30 Cr through internal accruals and promoter loans.

Credit Rating & Borrowing

CRISIL reaffirmed a 'CRISIL BBB-/Stable' long-term rating and 'CRISIL A3' short-term rating. Interest coverage ratio was 1.74 times in FY24. Borrowing costs are expected to decline following debt refinancing at lower rates in FY25.

⚙️ Operational Drivers

Raw Materials

The primary raw materials are imported plastic granules, which are used for bottle manufacturing and packaging. These materials are crude oil derivatives, making the company's cost structure highly sensitive to global oil price fluctuations.

Import Sources

Plastic granules are imported to ensure quality standards for parenteral products, though specific countries of origin are not listed beyond the requirement for high-grade medical plastics.

Key Suppliers

Not specifically named in the documents, but procurement is linked to global petrochemical markets for plastic granules.

Capacity Expansion

As of March 31, 2024, installed capacity includes 675 lakh bottles of Large Volume Parenteral (LVP), 2,400 lakh bottles of Small Volume Parenteral (SVP), and 849 lakh bottles of Steriport. The INR 90 Cr capex aims to significantly increase Steriport capacity by FY26.

Raw Material Costs

Raw material costs are a significant portion of the 55-60% revenue share attributed to the high-volume parenteral division. AHL manages these costs through a focus on higher-value products to offset the lack of bargaining power in low-value segments.

Manufacturing Efficiency

Manufacturing facilities in Kheda, Gujarat are ISO-certified and cGMP compliant. Efficiency is reflected in the sustained 20-22% operating margins despite raw material price pressure.

Logistics & Distribution

AHL utilizes an extensive distribution network of nearly 289 distributors to reach domestic and international markets.

📈 Strategic Growth

Expected Growth Rate

8-10%

Growth Strategy

Growth will be achieved through an INR 90 Cr capacity expansion in the Steriport segment, increasing the contribution of high-value-added products, and expanding export footprints. The company also filed a DRHP on September 26, 2024, to fund further capacity enhancements.

Products & Services

Large Volume Parenteral (LVP) and Small Volume Parenteral (SVP) for fluid therapy, formulations, antibiotics, anti-fungals, ophthalmic solutions, diuretics, and other injectables.

Brand Portfolio

Steriport (specialty parenteral brand).

New Products/Services

Expansion of the Steriport product line is expected to be the primary driver of the 8-10% revenue growth forecast for FY25.

Market Expansion

Targeting increased penetration in international markets such as Cambodia and Zimbabwe, supported by the Steriport capacity ramp-up through FY26.

Market Share & Ranking

AHL is described as one of the leading players in the parenteral business in India, though specific market share percentage is not provided.

Strategic Alliances

Engaged GoIndia Advisors LLP in January 2026 as an Investor Relations agency to manage capital market communications.

🌍 External Factors

Industry Trends

The parenteral industry is shifting toward high-value specialty injectables. AHL is positioning itself by expanding its Steriport capacity to move away from the low-margin, highly competitive standard LVP/SVP markets.

Competitive Landscape

Faces intense competition from both domestic and international parenteral manufacturers, particularly in the low-value fluid therapy segments.

Competitive Moat

Moat is built on the 'Steriport' brand, a large network of 289 distributors, and 30+ years of promoter experience. Sustainability depends on the successful transition to a higher-margin product mix to buffer against commodity price swings.

Macro Economic Sensitivity

Highly sensitive to global crude oil prices due to plastic granule requirements and domestic inflation which may affect operating costs.

Consumer Behavior

Increased demand for specialized fluid therapy and injectables in healthcare settings is driving the shift toward products like Steriport.

Geopolitical Risks

Trade barriers or regulatory changes in export markets like Cambodia and Zimbabwe could impact the projected growth from the export segment.

⚖️ Regulatory & Governance

Industry Regulations

Pricing is regulated by the National Pharmaceutical Pricing Authority (NPPA), which restricts the company's ability to pass on raw material price hikes to customers.

Environmental Compliance

Manufacturing facilities are ISO-certified and cGMP (current Good Manufacturing Practice) compliant, which are mandatory for pharmaceutical production.

⚠️ Risk Analysis

Key Uncertainties

Volatility in crude oil prices could impact operating margins by more than 200 basis points if costs cannot be passed on. The success of the INR 90 Cr capex is critical for maintaining the 8-10% growth trajectory.